Atritech raises $30m in financing

Published: 01-Apr-2009

Company to present the Protect AF results to the FDA's circulatory system devices panel in April 2009

Atritech, a US-based medical device company, has completed a $30m round of financing.

Thomas, McNerney & Partners led the round along with a substantial investment from Split Rock Partners and insider investments from Prism Ventures, Tullis-Dickerson and Vector Group.

With this new funding, the company will complete the FDA review of the Protect AF clinical trial results along with the commercial launch of the Watchman LAA closure technology in Europe. The Protect AF clinical trial evaluates the Watchman device versus the current standard of care, warfarin, in patients with atrial fibrillation.

In August 2008, Atritech filed its pre-market approval application to the FDA. The company will present the Protect AF results to the FDA's circulatory system devices panel in April 2009. The Watchman device continues to be implanted in a continued access registry while the product is under review at the FDA, said Atritech.

Jim Bullock, president and CEO of Atritech, said: After nine years in the development and clinical stage, we are ready to present our case to the FDA and launch commercial operations outside the US. Our results would be of significant interest to any patient with atrial fibrillation currently on warfarin therapy.

No items to display

Tell your friend about this article